Synapse - Department of Medicine

Results (39622)

A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC)

Meeting Abstract

Colevas, A. D.; Chung, C. H.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Sukari, A.; Worden, F. P.; Johnson, F. M.; Saba, N. F.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)

Meeting Abstract

Tap, W. D.; Somaiah, N.; Kang, Y. K.; Ryan, A.; Razak, A.; Garrido, M.; Desar, I. M. E.; Italiano, A.; Reichardt, P.; Wilky, B. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Ahsan, A.; Mantis, C.; Luo, X.; Zhang, C. C.; Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9

Meeting Abstract

Sborov, D. W.; Pawlyn, C.; Ishida, T.; Huang, J. S. Y.; Benjamin, R.; Iida, S.; Popat, R.; Kuroda, J.; Pianko, M. J.; Ramakrishnan, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS)

Meeting Abstract

Lacuna, K. P.; Ingham, M.; Chen, L.; Das, B.; Lee, S. M.; Ge, L.; Druta, M.; Conley, A. P.; Keohan, M. L.; Agulnik, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis

Meeting Abstract

Makker, V.; Richardson, D. L.; Chon, H. S.; Miller, D. S.; Mau-Sorensen, M.; Cibula, D.; Zagouri, F.; Fidalgo, A. P.; Slomovitz, B. M.; Coleman, R. L.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma

Meeting Abstract

Wang, Y.; Larson, M. C.; Kumar, A.; Hill, B. T.; Bond, D. A.; Kahl, B. S.; Danilov, A. V.; Merryman, R.; Grover, N. S.; Tun, A. M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC

Meeting Abstract

Deininger, M.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC)

Meeting Abstract

Lee, J. Y.; Ryoo, B. Y.; Kim, J. W.; Cheng, A. L.; Finn, R. S.; Hasegawa, K.; Makker, V.; Kudo, M.; Miller, D. S.; Merle, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)

Meeting Abstract

Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M. K.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save